Close Window

Digital Look Email A Friend

Novavax bosses sell $46m worth of stock with Covid-19 vaccine still in late trials

Published by Caoimhe Toman on 11th January 2021

(Sharecast News) - Top executives at US biotechnology company Novavax sold roughly $46m worth of the company's stock while its Covid-19 vaccine was still undergoing late stage clinical trials.

URL: http://www.digitallook.com/dl/news/story/31564982/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.